Another phase II GeparOLA trial also included patients with HER2-negative breast cancer and homologous recombination deficiency and showed that paclitaxel/olaparib did not improve pCRin gBRCA TNBC patients in comparison with paclitaxel/carboplatinum (NCT02789332) [34]. Here, ERBB2 is linked to hyperinsulinemic hypoglycemia, familial, 4.